Showing results (101-110 of 150) with videos related to
Sort By:
Pageof 15
Journal of Medicinal Chemistry|March 28, 2020
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC InhibitorsAshish Thakur, Gregory J Tawa, Mark J Henderson, et al.Blood|January 11, 2008
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cellsEllen Weisberg, Lolita Banerji, Renee D Wright, et al.Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.Leukemia|March 8, 2020
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.British Journal of Haematology|February 5, 2013
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemiaJulia Etchin, Takaomi Sanda, Marc R Mansour, et al.Molecular Cancer Therapeutics|September 3, 2010
Discovery and characterization of novel mutant FLT3 kinase inhibitorsEllen Weisberg, Hwan Geun Choi, Rosemary Barrett, et al.Cancer Letters|November 26, 2025
Profiling the genomic landscape and evolutionary history of polyploid giant cancer cells in undifferentiated pleomorphic sarcomasAmy L Bowes, Sara Waise, Tom Lesluyes, et al.Blood|June 10, 2011
Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AMLElspeth M Payne, Niccolò Bolli, Jennifer Rhodes, et al.Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Jacalyn Rosenblatt, Zekui Wu, Baldev Vasir, et al.Pageof 15